25.99
-0.21 (-0.80%)
| Previous Close | 26.20 |
| Open | 26.25 |
| Volume | 47,417 |
| Avg. Volume (3M) | 573,246 |
| Market Cap | 925,493,504 |
| Price / Sales | 14.99 |
| 52 Weeks Range |
| Profit Margin | -60.21% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -1.06 |
| Quarterly Revenue Growth (YOY) | 48.10% |
| Total Debt/Equity (MRQ) | 193.57% |
| Current Ratio (MRQ) | 2.67 |
| Operating Cash Flow (TTM) | -31.74 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | CeriBell, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.00 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 26.96% |
| % Held by Institutions | 39.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (TD Cowen, 38.52%) | Buy |
| Median | 32.50 (25.05%) | |
| Low | 32.00 (JP Morgan, 23.12%) | Buy |
| 32.00 (B of A Securities, 23.12%) | Buy | |
| Average | 33.25 (27.93%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 28.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 09 Dec 2024 | 33.00 (26.97%) | Buy | 30.04 |
| 13 Nov 2024 | 31.00 (19.28%) | Buy | 27.88 | |
| TD Cowen | 09 Dec 2024 | 36.00 (38.51%) | Buy | 30.04 |
| 05 Nov 2024 | 31.00 (19.28%) | Buy | 26.96 | |
| B of A Securities | 05 Nov 2024 | 32.00 (23.12%) | Buy | 26.96 |
| JP Morgan | 05 Nov 2024 | 32.00 (23.12%) | Buy | 26.96 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BLUMBERG SCOTT | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BLUMBERG SCOTT | Officer | 23 Dec 2024 | Option execute | 1,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |